Evidence map›Paper›PMID 39520894›Full record

ArticleVaccine2025

Proteomic signatures of vaccine-induced and breakthrough infection-induced host responses to SARS-CoV-2.

Erin Williams, Felipe Echeverri Tribin, Juan Manuel Carreño, Florian Krammer, Michael Hoffer, Suresh Pallikkuth, Savita Pahwa

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Erin WilliamsDepartment of Otolaryngology, University of Miami Miller School of Medicine, Miami, Florida, 33136, USA; Department of Biomedical Engineering, University of Miami, Miami, Florida, 33136, USA.
Felipe Echeverri TribinUniversity of Miami Miller School of Medicine, Miami, Florida, 33136, USA.
Juan Manuel CarreñoDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, NY, New York, 10029, USA; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Florian KrammerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, NY, New York, 10029, USA; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Ignaz Semmelweis Institute, Interuniversity Institute for Infection Research, Medical University of Vienna, Vienna, Austria.
Michael HofferDepartment of Otolaryngology, University of Miami Miller School of Medicine, Miami, Florida, 33136, USA; Department of Neurological Surgery, University of Miami, Miller School of Medicine, Miami, Florida, 33136, USA.
Suresh PallikkuthDepartment of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, Florida, 33146, USA.
Savita PahwaDepartment of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, Florida, 33146, USA.

Funding

COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025
$105.4M
University of Miami Developmental Center for AIDS Research (D-CFAR)P30AI073961 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI GWENDOLYN Barbara SCOTT · 2007 to 2026
$33.8M
NIAID NIH HHS 75N93019C00051NIAID NIH HHS P30 AI073961
6 · The paper itself

Abstract

The severity of SARS-CoV-2 illness is influenced by factors including age, sex, pre-existing health conditions, and individual immune responses. However, the mechanisms conferring immunity following antigenic challenge have not been fully elucidated. There are currently no studies evaluating longitudinal proteomic changes in individuals following vaccination and breakthrough, limiting our understanding of the underlying mechanisms driving conferred immunity. In this work, we evaluated the differential protein expression in individuals with (CoV-P) or without (CoV-N) prior SARS-CoV-2 infection following primary vaccination and after breakthrough infection (CoV-BT). Overall, we found that individuals receiving primary vaccination relied on innate immune mechanisms, including complement and coagulation cascades, and natural killer cell-mediated cytotoxicity, while conversely, breakthrough infection immune mechanisms relied on T cell-mediated immunity. These mechanistic differences may help explain heterogeneity associated with vaccine-induced and breakthrough infection-related outcomes.

Indexed as

COVID-19COVID-19 VaccinesProteomicsSARS-CoV-2AdultAgedBreakthrough InfectionsFemaleHumansImmunity, CellularImmunity, InnateKiller Cells, NaturalMaleMiddle AgedVaccinationCOVID-19 Vaccines“Proteomics”“SARS-CoV-2”“Vaccination”

Identifiers

PMID39520894
PMCPMC12044548

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.